Table 1. Minimal-Inhibitory Concentrations (MICs) of Oxadiazoles^a.

		MIC (μg/mL)
microorganism	2	3	4	vancomycin	linezolid
S. aureus ATCC 29213b	2	2	2	1	4
S. aureus ATCC 27660c	2	2	2	1	2
S. aureus NRS100 (COL)c	2	2	2	2	2
S. aureus NRS119d	2	2	2	2	32
S. aureus NRS120d	2	2	2	2	32
S. aureus VRS1e	2	2	2	512	2
S. aureus VRS2f	2	2	2	64	2
S. epidermis ATCC 35547	2	2	2	16	1
S. hemolyticus ATCC 29970	2	2	4	2	2
S. oralis ATCC 9811	32	32	32	0.5	1
S. pyogenes ATCC 49399	32	>32	32	0.6	1
B. cereus ATCC 13061	2	2	4	1	1
B. licheniformis ATCC 12759	2	2	2	0.5	1
E. faecalis ATCC 29212b	2	2	2	2	2
E. faecalis 201 (Van S)g	2	2	>32	1	2
E. faecalis 99 (Van R)h	2	2	2	128	1
E. faecium 119–39A (Van S)g	1	1	1	0.5	2
E. faecium 106 (Van R)h	2	2	2	256	1
E. faecium NCTC 7171	1	2	2	0.5	2

^aWhereas the compounds were screened against E. coli and the ESKAPE panel of bacteria, they exhibited antibacterial activity only against Gram-positive bacteria.

^bA quality-control strain to monitor accuracy of MIC testing.

^cmecA positive, resistant to methicillin, oxacillin, and tetracycline; susceptible to vancomycin and linezolid.

^dmecA positive, resistant to ciprofloxacin, gentamicin, oxacillin, penicillin, and linezolid.

^eVancomycin-resistant MRSA (vanA) clinical isolate from Michigan.

^fVancomycin-resistant MRSA (vanA) clinical isolate from Pennsylvania.

^gVancomycin-susceptible clinical isolate.

^hVancomycin-resistant clinical isolate.